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repair mechanisms, reduces inflammation,
and promotes cell survival (McElroy et al.,
2012). The reduction in EGFR signaling
observed by Campbell et al. (2014) is
therefore likely to be primarily respon-
sible for the lifelong diarrhea affecting
the child, which is analogous to the inflam-
matory bowel disease seen in the
ADAM17-null individuals described pre-
viously (Blaydon et al., 2011).
In addition to direct stimulation by its
seven ligands, EGFR signaling can also be
activated indirectly by the binding of unre-
lated ligands to their receptors on EGFR-
expressing cells, such as by vascular endo-
thelial growth factor-A and keratinocyte
growth factor (FGF7). In these processes,
binding of the ligands to their receptors
triggers the shedding of an EGFR ligand
(typically HB-EGF or TGFa) by an ADAM
protease in an Src- or ERK-dependent
manner; this ligand can then act as an
autocrine growth factor to activate the
EGFR. As such, signaling through the EGFR
underlies the activity of numerous growth
factors that are not direct EGFR ligands. For
example, migration of epithelial and
endothelial cells in response to FGF7 or
vascular endothelial growth factor-A, which
bind to specific, non-EGFR-related receptor
tyrosine kinases, requires Src-dependent
activation of ADAM17 and shedding of
HB-EGF (Maretzky et al., 2011). Therefore,
signaling through the EGFR is important in
cell migration and proliferation in a manner
that can be independent of its ligands.
EGFR transactivation also underlies the
gastro-protective effects of prostaglandins,
which are lipid mediators known to have
key roles in gastrointestinal defense and
regeneration (Pai et al., 2002). Prosta-
glandin inhibition by either nonsteroidal
inflammatory drugs or genetic disease
results in severe intestinal disease.
This study provides an interesting con-
trast to other, previously reported, inherited
epidermal diseases that also affect EGFR
signaling. In this study, the disease-asso-
ciated EGFR mutation increases the sus-
ceptibility of the EGFR to endocytosis,
thereby resulting in reduced downstream
EGFR signaling. By contrast, autosomal
dominant punctate palmoplantar kerato-
derma has been associated with mutations
in the clathrin-coated vesicle-associated
protein AAGAB, leading to reduced EGFR
endocytosis and increased EGFR signaling
(Pohler et al., 2012). Similarly, the inheri-
ted cutaneous disease tylosis with eso-
phageal cancer is characterized by upregu-
lated ADAM17 activity and EGFR ligand
shedding, also resulting in palmoplantar
keratoderma (Brooke et al., 2014).
Finally, the described mutation in this
case is located in the extracellular domain
III of the EGFR. Therapeutic mAbs targeting
the EGFR used for metastatic cancer, such
as cetuximab, bind to this domain. The
papulopustular eruptions described with
mAbs are generally more severe than those
caused by EGFR tyrosine kinase domain
inhibitors, illustrating the importance of the
extracellular domain III in skin homeostasis.
CONFLICT OF INTEREST
The authors state no conflict of interest.
REFERENCES
Blaydon DC, Biancheri P, Di WL et al. (2011)
Inflammatory skin and bowel disease linked to
ADAM17 deletion. N Engl J Med 365:1502–8
Brooke MA, Etheridge SL, Kaplan N et al. (2014)
iRHOM2-dependent regulation of ADAM17 in
cutaneous disease and epidermal barrier func-
tion. Hum Mol Genet; e-pub ahead of print
18 March 2014, doi:10.1093/hmg/ddu120
Campbell P, Morton P, Takeichi T et al. (2014)
Epithelial inflammation resulting from an
inherited loss-of-function mutation in EGFR.
J Invest Dermatol 134:2570–8
Chalaris A, Adam N, Sina C et al. (2010) Critical
role of the disintegrin metalloprotease
ADAM17 for intestinal inflammation and
regeneration in mice. J Exp Med 207:1617–24
Franzke CW, Cobzaru C, Triantafyllopoulou A
et al. (2012) Epidermal ADAM17 maintains
the skin barrier by regulating EGFR ligand-
dependent terminal keratinocyte differentia-
tion. J Exp Med 209:1105–19
Iwamoto R, Mekada E (2006) ErbB and HB-EGF
signaling in heart development and function.
Cell Struct Funct 31:1–14
Maretzky T, Evers A, Zhou W et al. (2011) Migra-
tion of growth factor-stimulated epithelial and
endothelial cells depends on EGFR transactiva-
tion by ADAM17. Nat Commun 2:229
McElroy SJ, Hobbs S, Kallen M et al. (2012) Trans-
activation of EGFR by LPS induces COX-2
expression in enterocytes. PLoS One 7:e38373
Pai R, Soreghan B, Szabo IL et al. (2002) Prostaglandin
E2 transactivates EGF receptor: a novel mechan-
ism for promoting colon cancer growth and
gastrointestinal hypertrophy. Nat Med 8:289–93
Pohler E, Mamai O, Hirst J et al. (2012) Haploin-
sufficiency for AAGAB causes clinically het-
erogeneous forms of punctate palmoplantar
keratoderma. Nat Genet 44:1272–6
See related article on pg 2589
Metformin: A Potential Drug to Treat
Hyperpigmentation Disorders
Elisabeth S. Belisle1 and Hee-Young Park1
Hyperpigmentation disorders are generally difficult to treat because of the limited
availability of effective therapeutics with minimal side effects. In this issue,
Lehraiki et al. report that metformin, an antidiabetic drug, inhibited melanogen-
esis, in vitro and in vivo, and they suggest that metformin may be used to treat
hyperpigmentation disorders. This commentary reviews the molecular mechan-
isms through which metformin inhibits melanogenesis and examines metformin as
a potential drug to treat hyperpigmentation.
Journal of Investigative Dermatology (2014) 134, 2488–2491. doi:10.1038/jid.2014.245
Metformin suppresses the levels of key
melanogenic proteins
Metformin is an antidiabetic drug
that is known to exert biological
effects by inhibiting the energy-sensitive
AMP-activated protein kinase (AMPK)–
mammalian target of rapamycin (Viollet
et al., 2012). Recently, metformin was
shown to decrease intracellular levels
of cyclic adenosine monophosphate
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(cAMP) (Miller et al., 2013). Because
cAMP is a well-known modulator
of melanin synthesis (melanogenesis),
Lehraiki et al. (2014) investigated whe-
ther metformin can modulate melano-
genesis.
When melanocytes were treated with
metformin, basal levels of total melanin
were reduced significantly. In addi-
tion, metformin blocked foreskolin
and a-melanocyte-stimulating hormone
(a-MSH)-induced increases in the levels
of melanin (Lehraiki et al., 2014). In
order to elucidate the mechanisms by
which metformin inhibits melano-
genesis, the effects of metformin on
the levels of three key melanogenic
proteins—tyrosinase, tyrosinase-related
protein-1 (TRP-1), and tyrosinase-related
protein-2 (TRP-2)—were examined
using immunoblot analyses. There are
two types of melanin: dark, brown-
black eumelanin and light, red-yellow
sulfur-containing pheomelanin. Synth-
esis of both types of melanin involves
a rate-limiting catalytic step in which
the amino acid tyrosine is oxidized by
tyrosinase to L-DOPA. This first step is
thought to be the critical rate-limiting
step in melanogenesis, as inhibition of
this reaction blocks melanin synthesis.
L-DOPA is then oxidized into DOPA-
quinone and converted to 5,6-dihydrox-
yindole or 5,6-dihydroxyindole-2-
carboxylic acid by TRP-2. The role of
TRP-1 in human melanogenesis is not
well characterized, but genetic muta-
tions in TRP-1 in humans result in
hypopigmentation, suggesting that TRP-1
has a key role in melanin synthesis
(reviewed in Park and Yaar, 2012).
Consistent with the effects of metformin
on total levels of melanin, metformin
decreased the basal levels of tyrosinase,
TRP-1, and TRP-2, and it blocked fore-
skolin and a-MSH-induced increases in
these three key melanogenic proteins
(Lehraiki et al., 2014).
Metformin downregulates the expression
of microphthalmia-associated
transcription factor (MITF) through a
cAMP-dependent pathway
MITF, a basic–helix–loop–helix and leu-
cine zipper transcription factor, has been
termed the ‘‘master gene’’ for melano-
cyte survival, and it is a key factor
regulating transcription of the major mel-
anogenic proteins such as tyrosinase,
TRP-1, TRP-2, protein kinase C-b (PKC-
b), and MART-1 (reviewed in Park and
Yaar, 2012). Moreover, it is well docu-
mented that the expression of MITF is
upregulated by a cAMP-dependent
pathway. When a-MSH binds to its
melanocortin 1 receptor, intracellular
levels of cAMP are elevated through
the activation of the membrane-
associated adenylate cyclase enzyme
(see Figure 1). The cAMP-dependent
protein kinase A enzyme is then acti-
vated, and it translocates to the nucleus
and phosphorylates the cAMP-respon-
sive element-binding protein (CREB).
CREB then binds its DNA consensus
sequence CRE in the promoter region
of the MITF gene, thereby inducing
MITF transcription (see Figure 1). Taking
advantage of this knowledge, Lehraiki
et al. (2014) treated melanocytes with
metformin and examined its effects on
the intracellular levels of cAMP, activa-
tion of protein kinase A, and phosphory-
lation of CREB, as well as on the levels
of MITF. Their results showed that
metformin reduced basal levels and
inhibited foreskolin- and a-MSH-induced
increases in the activities of protein kinase
A and CREB phosphorylation, as well
as increased cAMP accumulation and
the levels of MITF. Thus, the authors
concluded that metformin inhibits
melanogenesis by downregulating the
expression of MITF through a cAMP-
dependent pathway.
Although the AMPK pathway has not
been implicated in regulating melano-
genesis, it has been well documented
that AMPK is one of the major mediators
of metformin’s biological effects.
Lehraiki and colleagues thus examined
a possible role for AMPK in inhibiting
melanogenes by metformin. Melano-
cytes were transfected with control or
dominant-negative AMPK, as well as
control siRNA or siRNA against AMPK.
Interestingly, neither dominant-negative
AMPK nor siRNA against AMPK blocked
the inhibitory effects of metformin
on melanogenesis. These results demon-
strated that AMPK is not involved in
mediating the inhibitory effects of met-
formin on melanogenesis.
Studies have shown that Wnt/b-cate-
nin also has an important role in the
expression of MITF (Bellei et al., 2010).
Treatment of melanocytes with met-
formin resulted in downregulation of
phosphorylated b-catenin in both basal
and forskolin-stimulated conditions, but
the transcriptional activity of b-catenin
induced by foreskolin was not affected
by metformin, suggesting that the Wnt/b-
catanin pathway is not involved in
mediating the inhibitory effects of
metformin on melanogenesis.
Both PKC and cAMP-dependent path-
ways were implicated in the crosstalk
that regulates melanogenesis (Ao et al.,
1998). Endothelin-1 and histamine were
also shown to utilize both PKC and
cAMP-dependent pathways to exert
their regulatory effects on melanocyte
function (reviewed in Park and Yaar,
2012). Therefore, it is possible that
metformin utilizes both PKC and
cAMP-dependent pathways to exert its
biological actions. Indeed, it was shown
that metformin could inhibit the
activation of PKC-b (Batchuluun et al.,
2014), and PKC-b has been well
documented to regulate melanogenesis
(reviewed in Park and Yaar, 2012). PKC
is a serine/threonine kinase C that is
activated by diacylglycerol, a component
cleaved from the plasma membrane
when cell surface receptors interact
with their ligands. Diacylglycerol
induces PKC translocation to mem-
branes, where the latter is activated to
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induce phosphorylation of serine/
threonine residues on target proteins
such as tyrosinase (see Figure 1). The
PKC-b isoform is specifically involved in
regulating tyrosinase activity. When
activated by diacylglycerol, it interacts
with receptor-activated C-kinase and
then anchors onto melanosomes, the
organelle where melanogenesis occurs,
and phosphorylates tyrosinase. Phos-
phorylation activates tyrosinase (see
Figure 1). Therefore, the decrease in
pigmentation caused by metformin and
observed by Lehraiki et al. (2014) may
also involve the inhibition of tyrosinase
activity through the inhibition and
activation of PKC-b. MITF has also
been shown to regulate the expression
of PKC-b (Park et al., 2006), suggesting
that metformin may utilize both cAMP
and PKC-dependent pathways to
downregulate melanin synthesis.
Metformin decreases pigmentation in vivo
Lehraiki et al. (2014) also demonstrated
that metformin decreased skin pigmen-
tation in vivo with minimal side effects,
suggesting a potential application of
metformin in the treatment of hyper-
pigmentation disorders. When metfor-
min was applied topically onto a mouse
tail, whitening of the tail was observed.
In addition, metformin decreased the
epidermal level of melanin when
metformin was applied to human skin
punch biopsies and to reconstructed
human epidermis. A similar result was
reported when bisindolylmaleimide, a
PKC inhibitor, was applied topically to
mouse skin (Park et al., 2004; Figure 2).
These results suggest strongly that
inhibition of PKC and/or the cAMP-
dependent pathway will decrease
pigmentation in vivo and thus provide
specific targets in the development of
novel therapeutics.
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Figure 1. Potential inhibitory target sites of metformin: a-melanocyte-stimulating hormone (MSH) binding to melanocortin 1 receptor activates the enzyme
adenylate cyclase, leading to increased cyclic adenosine monophosphate (cAMP) levels. Metformin blocks increases in intracellular levels of cAMP, thus reducing
the activation of protein kinase A (PKA), which results in downregulation of the expression of microphthalmia-associated transcription factor (MITF). A decrease in
MITF leads to decreased levels of melanogenic proteins. Diacylglycerol (DAG) released from the cell membrane in response to exogenous signals such as UVR
activates protein kinase C (PKC)-b, which then binds to receptor-activated C-kinase-1 (RACK-1) and phosphorylates serine residues on tyrosinase, thereby
activating the enzyme. Bisindolylmaleimide (Bis) and metformin can inhibit PKC-b-mediated activation of tyrosinase. Decreased levels of MITF and inhibition of
PKC-b lead to reduced melanogenesis.
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Figure 2. Mouse coat color is lightened by bisindolylmaleimide (Bis) treatment. Nine-week-old black
mice were depilated to synchronize the hair cycle and initiate a new anagen growth phase. Beginning 3
days later, either 100mM of Bis (top) or vehicle alone (bottom) was topically applied once a day for 9 days,
and the mice were photographed on day 13. Inset: hair from Bis or vehicle-treated areas was plucked on
day 13 and photographed under a dissecting microscope. Representative hairs (midshaft, B0.3mm in
length) from 50 hairs plucked from each area are shown (Park et al., 2004).
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However, caution should be taken
with respect to the chronic use of
metformin. MITF has been suggested to
be a key transcription factor for the
survival and proliferation of melano-
cytes. MITF was shown to upregulate
the expression of a major antiapoptotic
protein Bcl2, thus promoting the survival
of melanocytes (McGill et al., 2002). In
addition, MITF can induce or suppress
the melanocyte growth, depending on
the physiological conditions, by
modulating the expression of the cell
cycle–associated proteins such as kinase
Cdk2 and p21, a protein that inhibits
Cdk2 activation. Because MITF coop-
erates with other transcription factors to
induce its effects, it is to be expected that
these transcription factors would influ-
ence MITF activity, resulting in either
stimulation or inhibition of melanocyte
proliferation (reviewed in Park and Yaar,
2012). Therefore, prolonged exposure of
melanocytes to metformin may alter the
proliferation and/or survival of melano-
cytes. A more ideal drug to inhibit
pigmentation might target tyrosinase, an
enzyme, or its pathways that function
primarily to regulate pigmentation.
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Cells of Origin in Skin Cancer
Ju¨rgen C. Becker1 and Axel zur Hausen2
Adult skin stem cells do not protect their genome by asymmetric chromosome
segregation; thus, they are prone to accumulating oncogenic mutations.
Journal of Investigative Dermatology (2014) 134, 2491–2493. doi:10.1038/jid.2014.233
It is widely accepted that genetic and
epigenetic aberrations have a strong
impact in determining the tumor phe-
notype. However, it is also accepted
that the cell of origin of a cancer affects
the tumor phenotype in a similar man-
ner. The cells of origin acquire the first
genetic or epigenetic hit or hits that
culminate in the initiation of cancer,
but they still retain some of their char-
acteristics, such as migratory capacity
(Gupta et al., 2005). For most types of
solid cancers, the cell of origin is still
unknown.
Identifying cells of origin of solid
cancers remains a challenging task in
cancer biology (Visvader, 2011). This
concept, however, is less applicable
to skin cancer. Indeed, skin is one of
the organs most suitable for examining
this question experimentally: (i) skin is
highly accessible; (ii) skin stem- and
transit-amplifying cell compartments
are well defined; and (iii) mouse
models of melanocytic and epithelial
skin cancers that recapitulate many of
the features of human cancers have now
been established. Nevertheless, there is
still room for new—and sometimes
unexpected—discovery.
Basal cell carcinoma (BCC) is the
most common type of skin cancer; as a
matter of fact, it is the most common
cancer in humans. The nomenclature
for BCC is explained by the histomor-
phological resemblance of cancer cells
to basal cells of the epidermis. Nearly
all BCCs exhibit constitutive activation
of the Hedgehog (Hh) signaling pathway
(Hahn et al., 1996). This pathway was
first identified in Drosophila melano-
gaster, but it is highly conserved,
from insects to vertebrates. Sonic
hedgehog (SHH) is the best-studied
ligand of the vertebrate pathway: In
response to binding of SHH to its
receptor patched-1 (Ptch1), Ptch1 stops
inhibiting smoothened (Smo), which
subsequently results in activation of the
GLI transcription factors. Loss of hetero-
zygosity of Ptch1 or activating mutations
in Smo can be detected in most forms
of BCC.
The observation that Hh signaling
represents the oncogenic driver aberra-
tion in BCC allowed the use of lineage
fate experiments to identify the cells
of origin of BCC. Only cancers with
known oncogenic driver genes allow
taking advantage of cell-specific Cre
expression to activate the respective
signaling pathway in the cell of
interest, and thus the possibility of
induced tumorigenesis. For BCC,
aberrant Hh signaling was clearly con-
firmed in mouse models. However,
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